secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aptose Biosciences Inc. (APTOF)
CIK:        0000882361
Form:       8-K
Filed at:   2025-01-21T23:59:59+00:00
Accession:  0001193125-25-009627
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 3.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aptose gets Nasdaq delisting notice for low bid price; reverse split vote Jan 27
--------------------------------------------------------------------------------

- Received Staff letter Jan 14, 2025 for failing $1 minimum bid price for 30 consecutive days.
- Must regain compliance by March 31, 2025 or present plan to hearings panel.
- Special shareholders' meeting Jan 27, 2025 to approve reverse stock split.
- Common shares continue to trade on TSX; unaffected by Nasdaq status.
- No assurance of regaining compliance with Nasdaq listing rules.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882361/000119312525009627/0001193125-25-009627-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882361/000119312525009627/d877128d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-009627

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer